On the heels of a $6.9B As­traZeneca pact, IP dis­pute be­tween Dai­ichi Sankyo and Seat­tle Ge­net­ics rips open in law­suit

A long-run­ning col­lab­o­ra­tion on ADC tech with Seat­tle Ge­net­ics that end­ed 4 years ago has come back to haunt Dai­ichi Sankyo.

Sev­en months af­ter As­traZeneca stepped up with a record-set­ting $6.9 bil­lion deal to li­cense a high­ly promis­ing can­cer drug that ap­pears poised for a near-term ap­proval, Dai­ichi Sankyo has called up the le­gal troops to fight back in court against Seat­tle Ge­net­ics’ claim to their IP, stem­ming from their tech al­liance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER